ERBB2 and carcinoma: In more than half of the rest of the cases in this group, immunohistochemical assessments revealed that many of the tumors (12 cases—46%) were luminal A-type carcinomas, followed by luminal B-type carcinomas (14.3%) and Her2-positive tumors (10.2%).